Is Waters Corporation profitable in 2026?

Yes. Waters reported Q1 2026 adjusted EPS of $2.70 (beating estimates of $2.31) on total revenue of $1.267 billion as of May 5, 2026, and raised full-year 2026 adjusted EPS guidance to $14.40 to $14.60, reflecting continued profitability post BD merger.

Did Waters Corporation merge with BD?

Yes. Waters completed a Reverse Morris Trust combination with BD's Biosciences & Diagnostic Solutions business on February 9, 2026, valued at approximately $17.5 billion, with legacy Waters shareholders retaining about 60.8% of the combined company.

Could AI replace Waters Corporation's products?

Unlikely for hardware. Waters' core revenue comes from physical, regulated LC/MS instruments and FDA-cleared diagnostics requiring calibration and validation. AI is being added as a software feature, like the June 24, 2026 IMU Biosciences AI-immunology partnership, not as a hardware replacement.

Who is Waters Corporation's biggest competitor?

Thermo Fisher Scientific is often cited as the largest rival, shipping AI-driven mass-spec workflows on its Orbitrap Exploris platform in August 2025. Other major competitors include Agilent Technologies, Danaher (SCIEX), Bruker, Shimadzu, and Revvity, per Wikipedia's competitor listing.

How many employees does Waters Corporation have in 2026?

Sources conflict. Macrotrends and StockAnalysis report about 7,900 employees as of December 31, 2025 (likely pre-merger), while aggregator estimates from Crustdata cite roughly 11,917 by July 2026 after absorbing BD Biosciences staff; the exact current figure is unverified pending Waters' next 10-K.

What did Waters Corporation guide for full-year 2026?

On May 5, 2026, Waters raised its FY2026 organic constant-currency revenue growth guidance to 6.5 to 8% and adjusted EPS guidance to $14.40 to $14.60, citing synergies from the BD Biosciences & Diagnostic Solutions combination completed February 9, 2026.

Biotech tools companies · United States

Waters Corporation

waters.com ↗

Makes chromatography and mass spec instruments for pharma, diagnostics, and food safety labs.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from Aug 4, 2026 · Every call on the record Checkpoint: Q2 2026 earnings call, second full quarter reporting combined Waters plus BD Biosciences

The call

Waters just doubled down on regulated lab lock-in with the BD deal, betting integration goes smoother than most mergers this size.

Waters Corporation builds and sells machines that test samples in hospitals, research labs, and drug companies. These machines are difficult to replace because hospitals and labs have to re-test and get government approval if they switch to a competitor's equipment, which costs time and money. Thermo Fisher is trying to use artificial intelligence to make their testing software faster and cheaper, but this does not threaten Waters' core business because the actual machines and the recurring revenue from replacement parts and services remain locked in. The big question is whether Waters can successfully combine its business with BD (a diagnostics company it is buying in early 2026) without slowing down its own growth or wasting money on the combination.

Why

AI pressure: Thermo Fisher's AI-driven mass-spec workflows (Orbitrap Exploris). AI-assisted workflow software from Thermo Fisher squeezes margins on the analytics layer, not the calibrated hardware underneath. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific. Bigger rival instruments compete directly in mass spec and chromatography but have not pulled share from Waters so far. Could a giant copy it? No, they are blocked.

What protects it. Regulated labs must revalidate any instrument swap, so Empower software and installed hardware lock customers in for years.

What would change this call

Waters Q2 2026 earnings call on Aug 4, 2026 reports organic growth and BD synergy figures. Shows whether BD integration is accelerating or stalling versus raised guidance.
Any disclosed loss of a marquee pharma account from Empower to a rival cloud LIMS/CDS platform. Would signal cracking of Waters' core software system-of-record lock-in.
Quarterly management commentary on China revenue trends through 2026. Two consecutive weak China quarters would indicate real regional demand erosion.

Key numbers

BD Biosciences deal closed at $17.5B, Feb 9, 2026 (2026-02-09)
Q1 2026 revenue $1.267B, EPS $2.70 vs $2.31 est (2026-05-05)
FY2026 EPS guidance raised to $14.40-$14.60 (2026-05-05)

Named risks

BD integration execution failure could force goodwill writedown or synergy downgrade. Severity: high
China market headwinds could drive consecutive guidance misses. Severity: medium
Loss of a marquee pharma account on Empower software to a rival cloud platform. Severity: medium
Headcount and organizational data conflict across sources, complicating integration tracking. Severity: low
Stock volatility (10-12% swings on earnings) signals market uncertainty over combined entity execution. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	contesting	Shipped AI-driven mass-spec workflows on Orbitrap Exploris platform, Aug 2025, pressuring software-layer margins
Agilent Technologies	contesting	Cited alongside Thermo Fisher as holding largest estimated shares in environmental mass-spec segment
Danaher (SCIEX)	contesting	Estimated next-tier market share (15-20%) alongside Waters in environmental mass-spec segment
Bruker Corporation	contesting	Listed as direct peer competitor in analytical instrumentation per Wikipedia

Questions people ask

Is Waters Corporation profitable in 2026?: Yes. Waters reported Q1 2026 adjusted EPS of $2.70 (beating estimates of $2.31) on total revenue of $1.267 billion as of May 5, 2026, and raised full-year 2026 adjusted EPS guidance to $14.40 to $14.60, reflecting continued profitability post BD merger.
Did Waters Corporation merge with BD?: Yes. Waters completed a Reverse Morris Trust combination with BD's Biosciences & Diagnostic Solutions business on February 9, 2026, valued at approximately $17.5 billion, with legacy Waters shareholders retaining about 60.8% of the combined company.
Could AI replace Waters Corporation's products?: Unlikely for hardware. Waters' core revenue comes from physical, regulated LC/MS instruments and FDA-cleared diagnostics requiring calibration and validation. AI is being added as a software feature, like the June 24, 2026 IMU Biosciences AI-immunology partnership, not as a hardware replacement.
Who is Waters Corporation's biggest competitor?: Thermo Fisher Scientific is often cited as the largest rival, shipping AI-driven mass-spec workflows on its Orbitrap Exploris platform in August 2025. Other major competitors include Agilent Technologies, Danaher (SCIEX), Bruker, Shimadzu, and Revvity, per Wikipedia's competitor listing.
How many employees does Waters Corporation have in 2026?: Sources conflict. Macrotrends and StockAnalysis report about 7,900 employees as of December 31, 2025 (likely pre-merger), while aggregator estimates from Crustdata cite roughly 11,917 by July 2026 after absorbing BD Biosciences staff; the exact current figure is unverified pending Waters' next 10-K.
What did Waters Corporation guide for full-year 2026?: On May 5, 2026, Waters raised its FY2026 organic constant-currency revenue growth guidance to 6.5 to 8% and adjusted EPS guidance to $14.40 to $14.60, citing synergies from the BD Biosciences & Diagnostic Solutions combination completed February 9, 2026.

Timeline

2026-07-20Stock drops 3% in a single day amid ongoing integration uncertainty
2026-06-24Waters Biosciences and IMU Biosciences announce AI-immunology platform partnership
2026-05-05Q1 2026 results beat estimates; FY2026 guidance raised to $14.40-$14.60 EPS
2026-02-09Waters completes $17.5B combination with BD Biosciences & Diagnostic Solutions
2025-08-04Q2 2025 revenue reported at $771 million, up 9% year over year
2025-07-14Waters and BD announce plan to combine Biosciences & Diagnostic Solutions businesses
2025-07-13SEC filing details BD deal terms: 39.2%/60.8% split, $4B debt, 2.3x leverage
2024-12-31Legacy Waters FY2024 revenue reported at approximately $2.958 billion

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE